Status:
ACTIVE_NOT_RECRUITING
The Effect of Combined Dulaglutide and Dapagliflozin Treatment vs DPP-4 Inhibitors in Endothelial and Vascular Function in Patients With Type 2 Diabetes Mellitus and Albuminuria
Lead Sponsor:
Attikon Hospital
Conditions:
Urine Albumin (UAlb)
Glycocalyx
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Patients with Type 2 Diabetes Mellitus and albuminuria will be randomised eitheer to dulaglutide and dapagliflozin combination or DPP-4 inhibitor, as an add-on treatment to metformin. Arterial stiffne...
Detailed Description
Patients with Type 2 Diabetes Mellitus and albuminuria will be randomised eitheer to dulaglutide and dapagliflozin combination or DPP-4 inhibitor, as an add-on treatment to metformin. Arterial stiffne...
Eligibility Criteria
Inclusion
- Type 2 diabetes mellitus Albuminuria HbA1c: 7-10% eGFR\> 60 ml/min
Exclusion
- Type 1 diabetes mellitus Inflammation, chronic or acute Established cardiovascular disease Malignancy within the last 5 years
Key Trial Info
Start Date :
February 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 15 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06611904
Start Date
February 1 2018
End Date
December 15 2024
Last Update
September 25 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Attikon University General Hospital
Chaïdári, Attica, Greece, 12462